Uveal melanoma, a rare form of eye cancer, develops when pigment-producing cells in the uvea-the middle layer of the eye-grow uncontrollably. It accounts for less than 1% of all cancers but is the most common primary intraocular malignancy in adults. Unlike skin melanoma, it is not typically linked to sunburns or tanning bed use.
The uvea includes the iris, ciliary body, and choroid. Melanoma in the eye usually begins in the choroid, the vascular layer behind the retina. While the exact trigger remains unclear, research identifies several contributing factors: genetic mutations, high levels of ocular pigmentation, and prolonged ultraviolet (UV) radiation exposure. The disease often progresses silently, with few early symptoms, making detection difficult until advanced stages.
According to the National Institutes of Health (NIH), approximately 6,000 cases of uveal melanoma are diagnosed annually in the United States. Most patients are between 50 and 70 years old at diagnosis. The condition affects men and women equally, though it is more frequently detected in people with lighter eye colors due to lower melanin protection.
Eye melanoma originates in melanocytes-cells responsible for producing melanin, the pigment that gives color to the skin, hair, and eyes. In the eye, these cells reside primarily in the choroid and iris. When DNA damage accumulates in these cells, mutations can cause uncontrolled growth. The most common mutation involves the GNAQ or GNA11 genes, which regulate cell signaling pathways. These mutations are present in over 90% of uveal melanomas, according to the American Cancer Society.
Unlike cutaneous melanoma, which is strongly associated with UV-induced DNA damage in skin cells, ocular melanoma's link to sunlight is indirect. UV exposure may contribute to oxidative stress in the eye's tissues over time, potentially increasing risk. However, the mechanism differs from skin cancer development. For example, a 2021 study published in *Ophthalmology* found no direct correlation between lifetime sun exposure and uveal melanoma incidence when adjusting for eye color and genetic markers.
Once initiated, tumor growth occurs slowly. Early-stage tumors may remain asymptomatic for months or years. As they enlarge, they can distort vision, cause flashes of light, or lead to blind spots. Because the eye lacks pain receptors, discomfort rarely signals the presence of a tumor until it compresses nearby structures.
Several well-documented risk factors increase the likelihood of developing melanoma in the eye:
A non-obvious fact: People with darker skin and eyes are not immune. Though less common, uveal melanoma can occur in individuals with dark pigmentation. A 2020 study in *Clinical Ophthalmology* reported that African American patients were more likely to be diagnosed at later stages due to delayed symptom recognition and healthcare access barriers.
Another misconception is that eye melanoma spreads easily. In reality, it metastasizes through the bloodstream, often to the liver. About half of patients develop metastasis within five years of diagnosis. Early detection improves survival rates -5-year survival exceeds 80% when localized, but drops below 20% once liver involvement occurs.
Many confuse ocular melanoma with benign conditions such as freckles on the iris (known as nevi) or floaters. While both can appear as dark spots in vision, they differ fundamentally. Iris nevi are stable, pigmented lesions that rarely progress to cancer. Floaters are small clumps of gel or cells floating in the vitreous humor-typically harmless and unrelated to melanoma.
For example, a 58-year-old woman noticed a dark spot on her iris during a routine eye exam. Initial concern led to ultrasound imaging, which confirmed a 3mm pigmented lesion. Biopsy results revealed no malignant cells. She was monitored every six months. After three years, the lesion remained unchanged. This case illustrates how benign pigmentation can mimic early melanoma but does not require treatment unless changes occur.
Some believe that eye melanoma is treatable only with enucleation (removal of the eye). Modern treatments include plaque brachytherapy, proton beam therapy, and targeted drug therapies. Survival rates have improved since the 1990s due to earlier detection and better local control methods.
Diagnosis relies on multimodal imaging. An ophthalmologist uses dilated eye exams, ultrasound, optical coherence tomography (OCT), and fundus photography to assess suspicious lesions. If a lesion shows irregular borders, thickness over 2 mm, or subretinal fluid, biopsy or monitoring is recommended.
Consider this case: A 62-year-old man with brown eyes reported a gradual loss of peripheral vision in his left eye. He had no pain or redness. Dilated exam revealed a 5mm dark mass in the posterior choroid. Ultrasound confirmed solid, elevated lesion. Fluorescein angiography showed hypervascularity. A fine-needle aspiration biopsy confirmed malignant melanoma. Treatment began with proton beam therapy, preserving vision and avoiding enucleation.
This example underscores that early detection saves sight. The American Cancer Society notes that regular complete eye exams reduce late-stage diagnoses by 30% in high-risk populations.
There is no proven way to prevent uveal melanoma. However, protecting eyes from UV light may reduce long-term cellular stress. Wearing sunglasses with 100% UV protection-especially during peak sun hours-can help. Avoiding tanning beds and minimizing exposure to intense artificial light sources may also be prudent.
People with light-colored eyes should consider annual eye exams after age 40. Those with a family history of melanoma or unusual pigmentation should consult an ophthalmologist specializing in ocular oncology.
Understanding what causes melanoma in the eye requires recognizing its unique biology. Unlike skin cancer, it arises from internal pigmented cells and progresses silently. Awareness of risk factors-especially eye color, age, and genetic markers-enables earlier intervention. Early detection remains the single most effective strategy against this rare but serious condition.